What specific financial results did the board approve?

The board approved the audited financial results for the quarter and full fiscal year ended March 31, 2026. The filing itself does not disclose the actual figures.

Why are no numbers in this announcement?

This is a cover letter announcing the board meeting outcome. The detailed financial statements are typically released in a separate, more detailed announcement.

Were any dividends or strategic changes announced?

No. The filing only mentions the approval of results and auditor appointments, with no mention of dividends or strategy shifts.

What does the appointment of new auditors signify?

It is a routine administrative step for the upcoming compliance cycle. The filing does not indicate any issue with the previous auditors.

Earnings · Pharmaceuticals · Micro cap

Phaarmasia approves FY26 results. The filing omits the numbers.

A procedural cover letter. The board signed off on annual results and named new auditors, but the actual financials are missing.

— 2 earlier stories on Phaarmasia Ltd. →

PHRMASI By Tipsheet Editorial 29 May 2026 · 7:18 PM IST Verify on BSE · NSE

Mkt cap₹68.47 cr

P/E3.90×

ROE0.00%

Debt / eq.0.00

₹53 cr Phaarmasia's market capitalisation.

What's new

Board approved audited results for Q4 and FY26 on March 31, 2026.
Appointed internal and secretarial auditors for the upcoming compliance cycle.
The filing contains no revenue, profit, or dividend figures.

Why this matters

This is a procedural milestone, not a financial update. The approval is a regulatory prerequisite for publishing the actual numbers. For a ₹53 crore nano-cap, the filing confirms the process is complete but gives the market nothing new to price.

What we're watching

The detailed financial statements in the separate announcement.
Whether the new auditors flag any qualifications in their report.
Any operational commentary from management on the FY26 performance.

The full read

Phaarmasia's board signed off on its annual results. That's the entire news. The cover letter approves the Q4 and FY26 numbers and names new auditors for the coming year. It provides no financial metrics, no dividend, and no operational detail. For a ₹53 crore nano-cap, the filing is a compliance checkbox. It is not a source of new information. The actual numbers will tell the story. They aren't here.

Questions answered

What specific financial results did the board approve?: The board approved the audited financial results for the quarter and full fiscal year ended March 31, 2026. The filing itself does not disclose the actual figures.
Why are no numbers in this announcement?: This is a cover letter announcing the board meeting outcome. The detailed financial statements are typically released in a separate, more detailed announcement.
Were any dividends or strategic changes announced?: No. The filing only mentions the approval of results and auditor appointments, with no mention of dividends or strategy shifts.
What does the appointment of new auditors signify?: It is a routine administrative step for the upcoming compliance cycle. The filing does not indicate any issue with the previous auditors.

Mentioned: Phaarmasia Ltd. · FY26 · March 31, 2026

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Phaarmasia Ltd.

Pharmaceuticals

₹66 cr

P/E 3.73×

Latest quarter · Mar 2026

Sales₹8 cr

Net profit−₹1 cr

Op. margin−8.6%

EPS−₹1.03

Strength & growth

Debt / equity0.00×

Current ratio0.65×

Sales CAGR+13.2%

EPS CAGR+81.5%

Story so far

All notes on PHRMASI →

29 May 2026 · 7:18 PM IST Phaarmasia approves FY26 results. The filing omits the numbers.
46d ago Phaarmasia's ₹17.57 cr profit is a one-off land sale
46d ago Phaarmasia's ₹18.99 cr land sale flips a ₹1.59 cr loss into a ₹17.57 cr profit